Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002416 · ClinicalTrials.gov registry record · Phase 3
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination
A Phase 3 study, sponsored by Triangle Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT00002416: Completed Phase 3 study, sponsored by Triangle Pharmaceuticals.
NCT00002416 is a Phase 3 study that has completed, run by Triangle Pharmaceuticals. The registered enrollment target is 390 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002416, a Phase 3 study, has completed, sponsored by Triangle Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.
Interventions
- DRUG Lamivudine
- DRUG Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002416
The ClinicalTrials.gov registry entry for NCT00002416 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Triangle Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lamivudine is the first listed.
NCT00002416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002416 about?
NCT00002416 is a clinical study titled "Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination". The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.
What is the current status of trial NCT00002416?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants.
What interventions are being tested in trial NCT00002416?
The interventions under investigation include: Lamivudine (DRUG), Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT00002416?
This trial is sponsored by Triangle Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.